Immuno Oncology

The success of an immuno-oncology therapeutic depends on much more than demonstrating that a molecule binds its target. Pharma and biotech teams need to understand whether that binding translates into the intended biological response, how immune cells interact with the therapeutic, how tumor cells respond, and whether unwanted immune activation may create safety concerns.

This is where well-designed in vitro immuno-oncology assays become critical. From early discovery through preclinical development and CMC, functional assays provide the evidence needed to select promising candidates, understand mechanism of action, compare molecules, establish potency, investigate resistance or tumor heterogeneity, and identify potential safety signals early.

At Boveevo, we bring together target-binding, immune-cell functional, tumor-cell killing, ADC characterization, bioassay, immunophenotyping, and cytokine profiling platforms to create a connected view of therapeutic performance.

In Vitro Services

✔️ T-cell-mediated tumour killing

✔️ NK-cell-mediated tumour killing

✔️ Immune-cell activation and proliferation

✔️ T-cell / NK-cell degranulation

✔️ ADCC / ADCP

✔️ Bispecific / T-cell engager assays

✔️ Cytokine profiling (Luminex & CBA)

✔️ Flow cytometry immunophenotyping

✔️ Intracellular cytokine staining

✔️ Incucyte live-cell killing and kinetic imaging

✔️ 3D tumour spheroid co-culture

✔️ Immune–tumour co-culture

✔️ Macrophage polarization

✔️ Macrophage phagocytosis

✔️ Combination and sensitization studies

✔️ Resistance-mechanism studies

In Vivo Studies

✔️ Xenograft Studies

✔️ Humanized animal models

✔️ Whole animal Imaging using IVIS

✔️ Biomarker analysis by

• Flow cytometer,

• Luminex and CBA

• qPCR/ddPCR

• Western Blot

• ELISA